Portable Soft Mist Inhaler for On-Demand Iloprost Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for administering inhaled Iloprost for pulmonary hypertension are cumbersome and do not facilitate as-needed (pro re nata) therapy, lacking portability and ease of use, which is essential for rapid onset of action and pulmonary selectivity.
Innovation Solution
The use of portable, pre-filled soft mist inhalers such as Respimat™ and Medspray™ for delivering Iloprost on an as-needed basis, allowing patients to inhale an effective dose of up to 5 μg at any time, providing a user-friendly and portable solution for acute treatment of pulmonary hypertension.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If conventional nebulizers are used for inhaled Iloprost administration, then therapeutic effects are achieved, but the administration process is cumbersome and lacks portability
Solution Approach 1:
The invention divides the medication delivery system into separate components: a portable inhaler device and a replaceable cartridge containing the Iloprost solution. This segmentation allows the main device to remain simple and portable while the cartridge handles the medication storage and delivery function, reducing overall operational complexity.
Solution Approach 2:
The Iloprost solution is pre-filled into cartridges during manufacturing, eliminating the need for patients to manually prepare or measure the medication at home. This preliminary action simplifies the patient's operation to merely attaching the cartridge and activating the inhaler, significantly reducing administrative burden.
2Ease of operation
If conventional nebulizers are used for inhaled Iloprost administration, then therapeutic effects are achieved, but portability is limited
Solution Approach 1:
The invention replaces traditional bulky nebulizer systems with a mechanically simpler portable inhaler that uses controlled airflow through a cartridge to generate aerosol. This substitution maintains therapeutic efficacy through proper aerosolization while dramatically improving portability and ease of use.
3Speed
If inhaled Iloprost is administered on an as-needed basis, then rapid onset of action is achieved, but conventional devices do not facilitate this usage pattern
Solution Approach 1:
The portable inhaler is designed with dynamic activation - the patient can initiate treatment immediately when needed by simply activating the device. The system responds dynamically to patient needs with rapid drug delivery, enabling true as-needed usage patterns that were not feasible with scheduled nebulizer treatments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables rapid and selective pulmonary vasodilation with significant therapeutic effects within minutes, improving exercise tolerance and daily activities, and reducing symptoms of pulmonary hypertension without systemic side effects, as demonstrated by clinical pilot studies.
Implementation Method 1
The use of portable, pre-filled soft mist inhalers such as Respimat™ and Medspray™ for delivering Iloprost on an as-needed basis
Data Source
AI summary
Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject an effective amount of iloprost on demand or as rescue medication (also referred to as pro re nata, PRN), wherein iloprost is administered to the subject via inhalation using a portable soft mist inhaler. In preferred embodiments, the soft mist inhaler is the Respimat™ or the Medspray™ wet aerosol inhaler.A method of treating a patient suffering from pulmonary hypertension, comprising:(a) providing a portable and pre-filled soft mist inhaler adapted for delivering an effective amount of iloprost; and(b) administering to the patient the effective amount of iloprost by inhalation on an as-needed basis.